Dr. Reddy's Laboratories Limited RDY
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing holdings can be maintained while new positions await confirmation of supply recovery.
Strong underlying base business and biosimilar pipeline are balanced against near-term semaglutide disruptions, regulatory risks and tariff threats, supporting a neutral stance.
The market continues to reflect concerns over semaglutide quality and delivery issues as well as regulatory observations, despite positive biosimilar news.
HOLD is the call. Negative is the market mood. Medium risk means some things can go wrong.
Latest change
- 24 Oct 2026 — Report shows revenue INR 86.8B and net income INR 9.2B, driven by strong growth in India and emerging markets despite North America decline.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Dr. Reddy's Laboratories is an Indian pharmaceutical company focused on generics, API manufacturing and biosimilars. The company has strong presence in the US, India and emerging markets plus a pipeline in GLP-1 and biologics. Operations are profitable with a solid balance sheet but face quality issues and regulatory risks.
Bull case
Biosimilar approvals and resumption of semaglutide shipments can drive growth once API issues are resolved.
Bear case
Semaglutide API quality problems, Form 483 observations and potential US tariffs continue to pressure margins.
Why this signal
Strong underlying base business and biosimilar pipeline are balanced against near-term semaglutide disruptions, regulatory risks and tariff threats, supporting a neutral stance.
Recent news
Q2 FY27 results were released on 23 October showing revenue of approximately 87 billion INR and net income around 9.2 billion INR. Semaglutide shipments are scheduled to resume in November after prior disruptions, while FDA inspections resulted in observations. North America sales dropped sharply due to lower generic lenalidomide revenue, but emerging markets and India showed strong growth.